Evidence Hub

Editorial: potassium‐competitive acid blockers for acid‐related diseases—tegoprazan, a new kid on the block

C. Scarpignato, R. Hunt

Alimentary Pharmacology and Therapeutics, 2019

20 citations

Abstract

1. Mandorfer M, Reiberger T. Editorial: pressure to close the therapeu‐ tic window of non‐selective betablockers? Aliment Pharmacol Ther. 2019;50:957‐958. 2. Tergast TL, Kimmann M, Laser H, et al. Systemic arterial blood pressure determines the therapeutic window of non‐selective beta blockers in decompensated cirrhosis. Aliment Pharmacol Ther. 2019;50:696‐706. 3. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304‐377. 4. Varpula M, Tallgren M, Saukkonen K, Voipio‐Pulkki LM, Pettila V. Hemodynamic variables related to outcome in septic shock. Intensive Care Med. 2005;31:1066‐1071. 5. Llach J, Gines P, Arroyo V, et al. Prognostic value of arterial pres‐ sure, endogenous vasoactive systems, and renal function in cir‐ rhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology. 1988;94:482‐487. 6. European Association for the Study of the Liver Electronic ad‐ dress: easloffice@easloffice eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the man‐ agement of patients with decompensated cirrhosis. J Hepatol. 2018;69:406‐460. 7. de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743‐752.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free